Gilder Gagnon Howe & Co’s Evolent Health EVH Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio EVH Stock Details EVH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-73,735	Closed	-$1.87M	–	290
2017 Q2	$1.87M	Sell	73,735 -187,831	-72%	-$4.52M	0.03%	186
2017 Q1	$5.83M	Sell	261,566 -67,668	-21%	-$1.3M	0.1%	136
2016 Q4	$4.87M	Sell	329,234 -199,543	-38%	-$3.93M	0.1%	123
2016 Q3	$13M	Buy	+528,777	New	+$12.4M	0.22%	86

Other funds holding EVH

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

CWAM

Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return

Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Gilder Gagnon Howe & Co's EVH Position: Q3 2017 in Review

Gilder Gagnon Howe & Co sold out of Evolent Health (EVH) in Q3 2017, closing a stake of 73,735 shares — an estimated $1.87M sold.

Gilder Gagnon Howe & Co first reported a position in EVH in Q3 2016 and held it in 4 quarters. The position peaked at $13M in Q3 2016. 166 funds tracked by Wall St. Rank hold EVH as of Q3 2017.

Gilder Gagnon Howe & Co reported no remaining Evolent Health position as of Q3 2017 after selling out during the quarter.
Gilder Gagnon Howe & Co sold 73,735 Evolent Health shares in Q3 2017, an estimated $1.87M.
Gilder Gagnon Howe & Co first reported a position in Evolent Health in Q3 2016 and held it in 4 quarters.
Gilder Gagnon Howe & Co's Evolent Health position peaked at $13M in Q3 2016.
166 funds tracked by Wall St. Rank held Evolent Health as of Q3 2017.

Based on Gilder Gagnon Howe & Co's 13F filing for Q3 2017, filed 6 Nov 2017.